These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33841165)

  • 21. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase.
    Pacl HT; Tipper JL; Sevalkar RR; Crouse A; Crowder C; ; Ahmad S; Ahmad A; Holder GD; Kuhlman CJ; Chinta KC; Nadeem S; Green TJ; Petit CM; Steyn AJC; Might M; Harrod KS
    bioRxiv; 2021 Jul; ():. PubMed ID: 34282419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Milan Bonotto R; Mitrović A; Sosič I; Martínez-Orellana P; Dattola F; Gobec S; Kos J; Marcello A
    Antiviral Res; 2023 Aug; 216():105655. PubMed ID: 37355023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern.
    Murer L; Volle R; Andriasyan V; Petkidis A; Gomez-Gonzalez A; Yang L; Meili N; Suomalainen M; Bauer M; Policarpo Sequeira D; Olszewski D; Georgi F; Kuttler F; Turcatti G; Greber UF
    Curr Res Virol Sci; 2022; 3():100019. PubMed ID: 35072124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitors targeting coronavirus and filovirus entry.
    Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
    Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
    El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
    Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.
    Sabarimurugan S; Dharmarajan A; Warrier S; Subramanian M; Swaminathan R
    Ann Transl Med; 2020 Oct; 8(19):1247. PubMed ID: 33178779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
    Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
    Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Cyclodextrins as affordable antivirals to treat coronavirus infection.
    Raïch-Regué D; Tenorio R; Fernández de Castro I; Tarrés-Freixas F; Sachse M; Perez-Zsolt D; Muñoz-Basagoiti J; Fernández-Sánchez SY; Gallemí M; Ortega-González P; Fernández-Oliva A; Gabaldón JA; Nuñez-Delicado E; Casas J; Roca N; Cantero G; Pérez M; Usai C; Lorca-Oró C; Alert JV; Segalés J; Carrillo J; Blanco J; Clotet Sala B; Cerón-Carrasco JP; Izquierdo-Useros N; Risco C
    Biomed Pharmacother; 2023 Aug; 164():114997. PubMed ID: 37311279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
    Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
    J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches.
    Lee HJ; Choi H; Nowakowska A; Kang LW; Kim M; Kim YB
    J Microbiol; 2023 Jul; 61(7):703-711. PubMed ID: 37358709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
    Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
    Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.